2Pitt B,Waters D,Brown WV,et al.Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease Atorvastatin versus Revascularization Treatment Investigator.N Engl J Med,1999,341:70-76. 被引量：1
3LaRosa JC,Grundy SM,Waters DD,et al.Intensive Lipid Lowering with Atorvastatin in Patients with stable coronary disease.N Engl J Med,2005,352:1425-1435. 被引量：1
4Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent Ischemic events in acute coronary syndromes:the MIRACL Study,a randomized controlled trial.JAMA,2001,285:1711-1718. 被引量：1
5Cannon CP,Braunwald E,Mccabe CH,et al.Pravastatin or atorvastatin evaluation and infection theraphy-thrombolysis in myocardial infarction 22 investigators.Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med,2004,350:1495-1504. 被引量：1
6de Lemos JA,Blazing MA,Wiviott SD,et al.Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndrome.Phase Z of the A to Z trial.JAMA,2004,292:1307-1316. 被引量：1
7Pedersen TR,Facrgeman O,John JP,et al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction.The IDEAL Study:a randomized controlled trial.JAMA,2005,294:2437-2445. 被引量：1
8Cannon CP,Steinberg BA,Murphy SA,et al.Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.J Am Coll Cardiol,2006,48:438-445. 被引量：1
9Faergeman O.High-dose atorvastatin or normal-dose simvastatin in treatment of patients with coronary heart disease (IDEAL trial)-secondary publication.Ugesker Laeger,2006,168:1769-1771. 被引量：1
10Arntz HR,Agrawal R,Wunderlich W,et al.Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event:the randomized Lipid-Coronary Artery Disease(L-CAD) Study JAMA.Am J Cardiol,2000,86:1293-1300. 被引量：1
6Rauoof MA,Iqbal K,Mir MM,et al.Measurement of plasma lipids in patients admitted with acute myocardial infarction or unstable angina peetofis.Am J Cardiol,2001,88:165-167. 被引量：1
7Nissen SE,Tuzcu EM,Schoenhagen P,et al.Reversal of aherosclerosis with aggressive lip id lowering (REVERSAL) investigators.Statin therapy,LDL cholestero,1 C2 reactive protein,and coronary artery disease.N Engl J Med,2005,352:29-38. 被引量：1
8[1]PatriciaAG, Kandice KM, Emilio DP, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001, 88:230 - 235 被引量：1
9[2]Mehta SR. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI- CURE[J] .J Invasive Cardiol, 2003,15(Suppl B): 17B - 20B 被引量：1
10[3]Simoons ML. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial[J].Lancet, 2001, 357(9272): 1915 - 1924 被引量：1
5Berns SA, Shmidt EA,Kiprina ES ,et al.Predictors of stent thrombosis in patients with ST-elevation acute coronary syndrome subjected to primary coronary artery interven- tion[J].Kardiologiia, 2011,51 (4) : 10-15. 被引量：1
6Medi C,Chew DPB,Amerena J,et al.An invasive man- agement strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease[J].Int Med J ,2011,41 (10) :743- 750. 被引量：1
7Henriksson M,Janzon M.Cost-effectiveness of ticagrelor in acute coronary syndromes[J].Expert Rev Pharmacoecon Outcomes Res ,2013,13( 1 ) :9-18. 被引量：1
9Young-Xu Y,Jabbour S,Goldberg R. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease[J].American Journal of Cardiology,2003.1379-1383. 被引量：1
10Matin F,Pascual DA,Roldan V. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting[J].American Journal of Cardiology,2006.55-60. 被引量：1
